Welcome to our dedicated page for Jasper Therapeutics news (Ticker: JSPR), a resource for investors and traders seeking the latest updates and insights on Jasper Therapeutics stock.
Jasper Therapeutics, Inc. (Nasdaq: JSPR) is a clinical-stage biotechnology company focused on developing briquilimab, an aglycosylated monoclonal antibody targeting KIT (CD117) for chronic mast cell diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma. The JSPR news feed highlights company announcements on clinical data, corporate developments and financing activities that shape the outlook for this mast cell–focused program.
News updates commonly cover clinical trial results and study updates. Jasper has reported data from the BEACON Phase 1b/2a study in CSU, an open-label extension study in chronic urticarias, and the ETESIAN Phase 1b/2a study in allergic asthma. These releases describe endpoints such as Urticaria Activity Score over 7 days (UAS7), hives and itch severity scores, airway hyperresponsiveness, sputum eosinophils, serum tryptase, and safety findings, including observations related to KIT blockade.
The JSPR news stream also includes corporate and strategic announcements, such as leadership changes, corporate reorganizations, and decisions to concentrate resources on briquilimab in mast cell driven diseases. Investors can find information on Jasper’s participation in healthcare and investor conferences, where management discusses briquilimab’s development and provides program updates.
In addition, Jasper issues financing and capital markets news, including details of public offerings of common stock, pre-funded warrants and common warrants, and stated uses of proceeds for advancing briquilimab and supporting general corporate purposes. Together, these news items provide context on clinical progress, strategic focus and funding for Jasper’s lead program. For readers tracking JSPR, this page offers a centralized view of the company’s press releases and related communications.
Jasper Therapeutics, Inc. (NASDAQ: JSPR) announced its participation in the William Blair 42nd Annual Growth Stock Conference in Chicago from June 6-9, 2022. CEO Ronald Martell will present on June 9 at 8:00 AM CT, followed by a breakout session at 8:40 AM CT. A live webcast of the presentation will be accessible on the company's investor webpage. Jasper Therapeutics is focused on stem cell therapies, advancing programs such as JSP191, aimed at safer hematopoietic cell transplants. For more information, visit jaspertherapeutics.com.
Jasper Therapeutics, Inc. (Nasdaq: JSPR) announced that its 2022 Annual Meeting of Stockholders will take place virtually on June 23, 2022, at 10:00 a.m. PT. Stockholders as of April 26, 2022, are eligible to participate and vote. The meeting will be accessible via a live audio webcast. Proxy materials with voting instructions have been distributed, and more details can be found on Jasper Therapeutics’ website and in the definitive proxy statement filed with the SEC on April 29, 2022.
Jasper Therapeutics, Inc. (NASDAQ: JSPR) has initiated a Phase 1/2 clinical trial at Stanford University to evaluate JSP191 as a conditioning agent for patients with Fanconi Anemia requiring bone marrow transplants. This research aims to improve donor stem cell engraftment while reducing toxicity. The trial is led by Dr. Rajni Agarwal and focuses on assessing treatment-emergent adverse events among participants. JSP191, previously tested in over 100 patients, is designed to facilitate safer allogeneic transplants. Jasper also plans further clinical trials expanding JSP191's applications.
Jasper Therapeutics reported a successful FDA meeting to initiate registrational studies for JSP191, focusing on patients with MDS and AML, expected by Q1-2023. Clinical data showed JSP191 was well tolerated, with 20 out of 24 patients free from disease progression. R&D expenses rose to $8.2 million due to increased trial costs. Cash reserves stood at $70.4 million, sufficient for operations through early 2023. The company aims to advance targeted therapies for hematopoietic stem cell transplants.
Jasper Therapeutics announced plans to initiate registrational studies for JSP191, a conditioning agent for older patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) undergoing transplants. After positive feedback from the FDA, the study protocol is being finalized with no additional studies required before initiation. Recent data showed JSP191 was well tolerated in 24 older patients with successful engraftment and minimal adverse events. The company aims to launch the study early next year, enhancing treatment outcomes for this vulnerable population.
Jasper Therapeutics (NASDAQ: JSPR) announced promising results from its Phase 1b trial of JSP191, an anti-CD117 monoclonal antibody, for treating older patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML). The study showed no treatment-related severe adverse events in 24 patients, all of whom achieved neutrophil recovery. Additionally, 20 patients were free from disease progression at the last follow-up. The company plans to initiate a registration study for JSP191 as a conditioning agent in upcoming hematopoietic stem cell transplants, aiming to improve treatment safety for older patients.
Jasper Therapeutics (NASDAQ: JSPR) will host a KOL webinar on April 28, 2022, at 1:00 p.m. ET, focusing on advancements in hematopoietic stem cell therapies. Key opinion leaders, Dr. Lori Muffly and Dr. David Sallman, will discuss the current challenges in stem cell transplant conditioning and myelodysplastic syndromes (MDS) treatment. The presentation will highlight JSP191, a targeted monoclonal antibody in clinical development, showcasing its potential in addressing transplant conditioning limitations for lower-risk MDS patients. A live Q&A session will follow the presentations.
Jasper Therapeutics (NASDAQ: JSPR) announced that updated data on JSP191, a monoclonal antibody, has been accepted for presentation at the 2022 Clinical Immunology Society Annual Meeting in Charlotte, NC, from March 31 to April 3. The study shows JSP191's potential to improve donor cell engraftment and immune reconstitution in severe combined immunodeficiency (SCID) patients who have failed previous transplants. CEO Ronald Martell emphasized the importance of this data for the SCID community, highlighting their commitment to delivering targeted therapies for these patients.
Jasper Therapeutics (Nasdaq: JSPR) announced on March 21, 2022, the granting of an option for 1,704,328 shares of common stock to new CEO Ronald Martell. This option, part of the 2022 Inducement Equity Incentive Plan, carries an exercise price of $3.54 per share and will vest over four years. Jasper focuses on hematopoietic cell transplantation therapies, notably advancing its anti-CD117 monoclonal antibody, JSP191, aimed at improving transplantation safety and effectiveness. The company remains committed to developing innovative therapies for life-threatening conditions.
Jasper Therapeutics (NASDAQ: JSPR) announced management changes effective March 21, 2022, including Jeet Mahal as Chief Operating Officer and Wendy Pang, M.D., Ph.D., as Senior Vice President of Research and Translational Medicine. A search for a Chief Medical Officer is underway. These moves aim to streamline operations and enhance clinical development for JSP191, a monoclonal antibody in clinical trials for AML/MDS. CEO Ronald Martell highlighted the need for a stronger organizational structure to support upcoming pivotal trials and pipeline execution.